Thomas Tueting (@ThomasTueting) profile picture
Magdeburg, Germany
Joined May 2019
We were priviliged to write a News & Views article on the fantaststic work by the group of Anja Obenauf that was published online in Nature Nov 27th (Elewaut et al. doi.org/10.1038/s41586-024-0…).  You can read it online with this SharedIt link: rdcu.be/d3cRz
1
5
14
1,635
Thomas Tueting retweeted
Thanks for the shoutout!
Cancer cells blunt monocyte IFN while increasing PGE2 to inhibit T cell immunity @Nature @obenaufa @AnaisElewaut @guillemxtivill nature.com/articles/s41586-0…
1
13
1,814
I feel very honored that the lab’s work has been awarded with the Georges-Köhler-Prize 🏆 from the German Society of Immunology @dgfi_org! Teamwork is essential to our work. Thanks to the whole team, its talented current and past members, & our fantastic collaboration partners!
This Post is from an account that no longer exists. Learn more
10
1
1
45
2,512
Thomas Tueting retweeted
Congratulations Matteo and co. for this beautiful study!
💥 Exciting News! Our latest research is now online @NatImmunol! Discover how prior infection or vaccination provides antibody-independent protection against heterologous SARS-CoV-2 challenge! 🧵🔬 (1/10) nature.com/articles/s41590-0… 2/ 🛡️ Shifting paradigms, our research highlights T cells' paramount role in defending against COVID-19 beyond antibody responses. Even in the complete absence of antibodies, T cells stand guard. 3/ 🧬 Our study utilized advanced mouse models, including a pioneering human/mouse ACE2 hybrid, to unveil that T cell immunity effectively counters various SARS-CoV-2 strains without relying on antibodies. 4/ 💪 Highlight of our findings: CD8+ T cells are crucial for combating severe infections, complemented by CD4+ T cells in less severe cases. The linchpin? Interferon-gamma (IFN-γ), driving this antibody-independent protection. 5/ 🔄 Demonstrated across models mimicking the spectrum of disease severity, this research shows that T cells not only prevent disease but also curb early SARS-CoV-2 replication. 6/ 📚 Building on the collective efforts of many in the field, our study underscores T cells' essential and sufficient role in safeguarding against SARS-CoV-2, reinforcing the critical importance of cellular immunity in the fight against COVID-19. 7/ 🌐 While our findings support vaccine strategies enhancing T cell responses, it's essential to acknowledge the efficacy of current vaccines in eliciting T cell immunity. We advocate for evaluating T cell responses alongside antibodies to fully assess vaccine effectiveness and explore targeted strategies for optimal T cell activation. 8/ 🙌 A heartfelt thank you to our incredible team and collaborators, especially lead author @ValeFuma91, along with key contributors Micol Ravà and Davide Marotta, as well as our collaborators Luca Guidotti, Marco Bianchi, and Raffaele De Francesco. 9/ 🌟Appreciation to our supporters @ERC, @AIRC_it, @EMBO_YIP, @ArmeniseHarvard, @mur_gov_, @SanRaffaeleMI, @MyUniSR, Fondazione SAME, Fondazione Prossimo Mio. Thanks also to our reviewers and Nick Bernard for their invaluable contributions to our journey. 10/ Dive deeper into our study to grasp its impact on immunology and future vaccine development. We're eager to hear your thoughts and engage in discussions! nature.com/articles/s41590-0…. Your feedback and insights are invaluable. 📖💭
2
1
6
3,352
Thomas Tueting retweeted
Very excited to share new work from the lab dissecting mechanisms of liver-metastatic organotropism in melanoma and other cancers. Huge congrats to fearless post-doc @meri_rogava (on the job market!) who led this multi-year study! Below a brief summary... nature.com/articles/s43018-0…
13
29
10
144
26,827
Thomas Tueting retweeted
Online Now: Interferon-stimulated neutrophils as a predictor of immunotherapy response dlvr.it/T10XST
1
69
3
227
27,151
Thomas Tueting retweeted
We celebrate the 20th anniversary of our lab with a paper just out in the 50th anniversary special issue of @CellCellPress A great way to start 2024! A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma: Cell cell.com/cell/fulltext/S0092…
14
36
9
170
34,821
Thomas Tueting retweeted
Proud to share our collaboration in the latest @CellCellPress paper led by @li_hanjie. The study presents an immune cell atlas & the dynamics of human macrophage specification in prenatal development. doi.org/10.1016/j.cell.2023.… (1/11)
5
106
7
387
82,288
Thomas Tueting retweeted
📢 Research Alert! 🧬🔬 🩺 We are super excited that our latest study, led by the great @RubenBill5 & Asa Wirapati, is out: science.org/doi/full/10.1126… We set out to shed some light on the tumor microenvironment and its impact on cancer progression. 🧵
6
30
7
122
22,038
1/ We're thrilled to share our preprint on Deep3P - a new approach that takes us on a deep dive into the world of brain tumors, using three-photon microscopy and #AI. This exciting endeavor is brought to life together with the amazing @Prevedel_Lab ! tinyurl.com/mpz3extr
7
39
12
177
67,600
Thomas Tueting retweeted
Thanks @Cancer_Cell for sharing, and grateful to reviewers and @Montse_Rojo_PhD for a constructive, engaging and fair review/revision process. Hard work by @triciahoho @JCA_Melms @meri_rogava with a product we are proud of.
Online Now: The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity dlvr.it/SqyWXh
3
4
1
32
6,221
Ein interdisziplinäres Forscherteam der @unimedmagdeburg entdeckt neuen Mechanismus der #Krebsimmunabwehr und liefert damit einen wichtigen Beitrag zur Verbesserung von #Krebs-#Immuntherapien. #TeamUMMD @Nature Mehr erfahren med.uni-magdeburg.de/News/Ma…
6
25
704
Thomas Tueting retweeted
My first first-author pub is finally out in @Cancer_Cell! Endless thanks to @BizarMd @JCA_Melms and @meri_rogava for all their guidance scientifically and personally that made this happen. Tweetorial below from our pre-print for now! authors.elsevier.com/c/1hFn3…
4
6
3
33
10,303
Australia - 1st authority in world to approve & fund #neoadjuvant pembrolizumab in resectable stage IIIB-D #melanoma. So proud of my co-med director @ProfRScolyerMIA - submitted with me on behalf @MelanomaAus. Neoadjuvant clinical trials critical for zero deaths from #melanoma.
10
44
12
193
32,803
Thomas Tueting retweeted
A special thanks to our great collaborators including @OBechter and funders including the VIB grand challenge program @VIBLifeSciences @vib_ccb @Onco_KULeuven @FWOVlaanderen @Stkstichting @MelanomaReAlli
1
2
10
1,265
Thomas Tueting retweeted
(Even a small amount of) CD4 T-cells can unleash a robust anti-tumour response through a rather unexpected mechanism…for more about this read this important paper from the Tüeting lab. Happy we could contribute to a small piece…
5
21
1,933
Thomas Tueting retweeted
A question that has long obsessed us: are the "seeds" of metastasis built into the primary tumor? In our new paper ,@shruthy_suresh tackled this question by combining human transcriptomics with the #Zebrafish TEAZ method to come up with the answer: doi.org/10.1158/2159-8290.CD…
6
13
2
90
Thomas Tueting retweeted
We are now utilizing our technologies to develop mRNA and LNP-based treatments effective at the cell level. So if you're interested in doing transformative biomedical research for patients' lives, check out our new position and pass it along. jobs.helmholtz-muenchen.de/j…
2
35
3
70